Personalized risk communication and opioid prescribing in association with nonprescribed opioid use: A secondary analysis of a randomized controlled trial.
acute pain management
narratives
opioids
patient decision aids
racial disparities
Journal
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
ISSN: 1553-2712
Titre abrégé: Acad Emerg Med
Pays: United States
ID NLM: 9418450
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
15
02
2023
received:
12
10
2022
accepted:
24
02
2023
medline:
31
7
2023
pubmed:
5
3
2023
entrez:
4
3
2023
Statut:
ppublish
Résumé
To determine the impact of personalized risk communication and opioid prescribing on nonprescribed opioid use, we conducted a secondary analysis of randomized controlled trial participants followed prospectively for 90 days after an emergency department (ED) visit for acute back or kidney stone pain. A total of 1301 individuals were randomized during an encounter at four academic EDs into a probabilistic risk tool (PRT) arm, a narrative-enhanced PRT arm, or a general risk information arm (control). In this secondary analysis, both risk tool arms were combined and compared with the control arm. We used logistic regressions to determine associations between receiving personalized risk information, receiving an opioid prescription in the ED, and nonprescribed opioid use in general and by race. Complete follow-up data were available for 851 participants; 23.3% (n = 198) were prescribed opioids (34.2% of White vs. 11.6% of Black participants, p < 0.001). Fifty-six (6.6%) participants used nonprescribed opioids. Participants in the personalized risk communication arms had lower nonprescribed opioid use odds (adjusted odds ratio [aOR] 0.58, 95% confidence interval [CI] 0.4-0.83). Black versus White participants had greater nonprescribed opioid use odds (aOR 3.47, 95% CI 2.05-5.87, p < 0.001). Black participants who were prescribed opioids had a lower marginal probability of using nonprescribed opioids versus those who were not (0.06, 95% CI 0.04-0.08, p < 0.001 vs. 0.10, 95% CI 0.08-0.11, p < 0.001). The absolute risk difference in nonprescribed opioid use for Black and White participants, respectively, in the risk communication versus the control arm, was 9.7% and 0.1% (relative risk ratio 0.43 vs. 0.95). Among Black but not White participants, personalized opioid risk communication and opioid prescribing were associated with lower odds of nonprescribed opioid use. Our findings suggest that racial disparities in opioid prescribing-which have been previously described within the context of this trial-may paradoxically increase nonprescribed opioid use. Personalized risk communication may effectively reduce nonprescribed opioid use, and future research should be designed specifically to explore this possibility in a larger cohort.
Sections du résumé
BACKGROUND
To determine the impact of personalized risk communication and opioid prescribing on nonprescribed opioid use, we conducted a secondary analysis of randomized controlled trial participants followed prospectively for 90 days after an emergency department (ED) visit for acute back or kidney stone pain.
METHODS
A total of 1301 individuals were randomized during an encounter at four academic EDs into a probabilistic risk tool (PRT) arm, a narrative-enhanced PRT arm, or a general risk information arm (control). In this secondary analysis, both risk tool arms were combined and compared with the control arm. We used logistic regressions to determine associations between receiving personalized risk information, receiving an opioid prescription in the ED, and nonprescribed opioid use in general and by race.
RESULTS
Complete follow-up data were available for 851 participants; 23.3% (n = 198) were prescribed opioids (34.2% of White vs. 11.6% of Black participants, p < 0.001). Fifty-six (6.6%) participants used nonprescribed opioids. Participants in the personalized risk communication arms had lower nonprescribed opioid use odds (adjusted odds ratio [aOR] 0.58, 95% confidence interval [CI] 0.4-0.83). Black versus White participants had greater nonprescribed opioid use odds (aOR 3.47, 95% CI 2.05-5.87, p < 0.001). Black participants who were prescribed opioids had a lower marginal probability of using nonprescribed opioids versus those who were not (0.06, 95% CI 0.04-0.08, p < 0.001 vs. 0.10, 95% CI 0.08-0.11, p < 0.001). The absolute risk difference in nonprescribed opioid use for Black and White participants, respectively, in the risk communication versus the control arm, was 9.7% and 0.1% (relative risk ratio 0.43 vs. 0.95).
CONCLUSIONS
Among Black but not White participants, personalized opioid risk communication and opioid prescribing were associated with lower odds of nonprescribed opioid use. Our findings suggest that racial disparities in opioid prescribing-which have been previously described within the context of this trial-may paradoxically increase nonprescribed opioid use. Personalized risk communication may effectively reduce nonprescribed opioid use, and future research should be designed specifically to explore this possibility in a larger cohort.
Substances chimiques
Analgesics, Opioid
0
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
851-858Informations de copyright
© 2023 Society for Academic Emergency Medicine.
Références
Singhal A, Tien YY, Hsia RY. Racial-ethnic disparities in opioid prescriptions at emergency department visits for conditions commonly associated with prescription drug abuse. PLoS One. 2016;11(8):e0159224. doi:10.1371/journal.pone.0159224
Burgess DJ, Crowley-Matoka M, Phelan S, et al. Patient race and physicians' decisions to prescribe opioids for chronic low back pain. Soc Sci Med. 2008;67(11):1852-1860.
Goyal MK, Kuppermann N, Cleary SD, Teach SJ, Chamberlain JM. Racial disparities in pain management of children with appendicitis in emergency departments. JAMA Pediatr. 2015;169(11):996-1002.
Netherland J, Hansen HB. The war on drugs that wasn't: wasted whiteness, “dirty doctors,” and race in media coverage of prescription opioid misuse. Cult Med Psychiatry. 2016;40(4):664-686. doi:10.1007/s11013-016-9496-5
James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018;46(2):404-421.
Drake J, Charles C, Bourgeois JW, Daniel ES, Kwende M. Exploring the impact of the opioid epidemic in black and Hispanic communities in the United States. Drug Sci Policy Law. 2020;6:205032452094042. doi:10.1177/2050324520940428
Swift SL, Glymour MM, Elfassy T, et al. Racial discrimination in medical care settings and opioid pain reliever misuse in a U.S. cohort: 1992 to 2015. PLoS One. 2019;14(12):e0226490. doi:10.1371/journal.pone.0226490
Meisel ZF, Goldberg EB, Dolan AR, et al. Stories to communicate individual risk for opioid prescriptions for back and kidney stone pain: protocol for the life storried multicenter randomized clinical trial. JMIR Res Protoc. 2020;9(9):1-16.
Meisel Z, Shofer F, Dolan A, et al. Multicentered randomized controlled trial comparing the effectiveness of pain treatment communication tools in emergency department patients with back pain or kidney stone pain. Am J Public Health. 2022;112(S1):S45-S55.
Opioid Risk Tool. National Institute on Drug Abuse. Accessed August 18, 2021. https://nida.nih.gov/sites/default/files/opioidrisktool.pdf
Engel-Rebitzer E, Dolan AR, Aronowitz SV, et al. Patient preference and risk assessment in opioid prescribing disparities: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2021;4(7):e2118801. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2782528
Dehon E, Weiss N, Jones J, Faulconer W, Hinton E, Sterling S. A systematic review of the impact of physician implicit racial bias on clinical decision making. Acad Emerg Med. 2017;24(8):895-904.
Way To Health. https://healthcareinnovation.upenn.edu/way-to-health
Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3(2):143-152. doi:10.1002/sim.4780030207
Raymond BL, Wanderer JP, Hawkins AT, et al. Use of the American College of Surgeons National Surgical Quality Improvement Program Surgical Risk Calculator during preoperative risk discussion: the patient perspective. Anesth Analg. 2019;128(4):643-650.
Sun D, Graham A, Feldmeyer B, Cullen FT, Kulig TC. Public opinion about America's opioid crisis: severity, sources, and solutions in context. Deviant Behav. 2022;1-24. doi:10.1080/01639625.2022.2071656
Gollust SE, Haselswerdt J. A crisis in my community? Local-level awareness of the opioid epidemic and political consequences. Soc Sci Med. 2021;291:4-13.
Nicholson HL, Ford JA. Correlates of prescription opioid misuse among black adults: findings from the 2015 National Survey on drug use and health. Drug Alcohol Depend. 2018;186:264-267.
Punches BE, Brown JL, Soliman S, et al. Patient pain experiences and the emergency department encounter: a qualitative analysis. Pain Manag Nurs. 2022;23(4):391-396.
Tamayo-Sarver JH, Hinze SW, Cydulka RK, Baker DW. Racial and ethnic disparities in emergency department analgesic prescription. Am J Public Health. 2003;93(12):2067-2073.
Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):70-78.
Chou SC, Deng Y, Smart J, Parwani V, Bernstein SL, Venkatesh AK. Insurance status and access to urgent primary care follow-up after an emergency department visit in 2016. Ann Emerg Med. 2018;71(4):487-496.e1. http://www.annemergmed.com/article/S0196064417315299/fulltext
Neprash HT, Gaye M, Barnett ML. Abrupt discontinuation of long-term opioid therapy among Medicare beneficiaries, 2012-2017. J Gen Intern Med. 2021;36:1-8. doi:10.1007/s11606-020-06402-z
Sinha CB, Bakshi N, Ross D, Krishnamurti L. Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic a qualitative study. JAMA Netw Open. 2019;2(5):1-9.
Zhang H, Kilaru AS, Meisel ZF, Bao Y. Prescription drug monitoring program mandates and opioids dispensed following emergency department encounters for patients with sickle cell disease or cancer with bone metastasis. JAMA. 2021;326:274-276.
Friedman JR, Hansen H. Evaluation of increases in drug overdose mortality rates in the US by race and ethnicity before and during the COVID-19 pandemic. JAMA Psychiatry. 2022;79(4):379-381. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2789697
Jannetto PJ, Helander A, Garg U, Janis GC, Goldberger B, Ketha H. The fentanyl epidemic and evolution of fentanyl analogs in the United States and the European Union. Clin Chem. 2019;65(2):242-253. https://academic.oup.com/clinchem/article/65/2/242/5607964
Nguemeni Tiako MJ. Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. J Subst Abuse Treat. 2020;122:108214. https://linkinghub.elsevier.com/retrieve/pii/S0740547220304712
Hansen HB, Roberts SK. Two tiers of biomedicalization: methadone, buprenorphine, and the racial politics of addiction treatment. Crit Perspect Addict. 2012;14:79-102. https://www.emerald.com/insight/content/doi/10.1108/S1057-6290(2012)0000014008/full/html.